Aribio said on the 23rd that it signed a $230 million (330 billion won) technology transfer contract with U.S. corporations Lestari. It is an export of technology for new drug candidate substances for kidney and liver diseases. The amount includes the contract upfront payment and milestones to be paid when stages such as clinical trials and approvals deliver results. After product launch, royalties linked to sales will be paid separately.
Using Aribio's next-generation phosphodiesterase (PDE)-5 inhibitor new drug technology, Lestari can develop and commercialize treatment programs. The company said the contract is distinct from the oral Alzheimer's treatment candidate (AR1001).
An Aribio official said it "will present practical treatment alternatives to patients."